Effect of a novel potential atypical antipsychotic drug, Y-931, in producing dystonia in cebus monkeys.
The effect of Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)-6H-[1]benzothieno[2,3-b][1,5]benzodiazepine maleate), a novel potential atypical antipsychotic candidate, in producing dystonia in Cebus monkeys was investigated. Y-931 induced relatively weak dystonia in several observation periods at doses greater than 0.1 mg/kg, i.m. Although Y-931 significantly increased total dystonia scores (the sum of 15 to 360 min after injection) at doses greater than 0.5 mg/kg, i.m., the scores did not exceed 20, up to a dose of 1.0 mg/kg, i.m. and lacked a dose-response relationship. The present result suggests that Y-931 is predicted to have a low risk of extrapyramidal side effects.
Shiigi
Yasuyuki
Y
Research Laboratory I (CNS), Pharmaceuticals Research Unit, Research & Development Division, Mitsubishi Pharma Corporation, Iruma, Saitama, Japan. Shiigi.Yasuyuki@md.m-pharma.co.jp
Maeda
Jun-ichi
J
Yasumatsu
Hiroshi
H
Tanaka
Hiroshi
H
Casey
Daniel E
DE
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000633:toxicity*; D001569:Benzodiazepines / Q000009:adverse effects / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004421:Dystonia / Q000139:chemically induced* / Q000503:physiopathology; D005260:Female; D010879:Piperazines / Q000009:adverse effects / Q000633:toxicity*
C434584:8-fluoro-12-(4-methylpiperazin-1-yl)-6H-(1)benzothieno(2,3-b)(1,5)benzodiazepine; D014150:Antipsychotic Agents; D010879:Piperazines; D001569:Benzodiazepines